{"id":"rtx-infusions","safety":{"commonSideEffects":[{"rate":"20-30","effect":"Infusion reactions"},{"rate":"15-25","effect":"Infections"},{"rate":"5-15","effect":"Cytopenias"},{"rate":"10-20","effect":"Fatigue"},{"rate":"5-10","effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL17976","moleculeType":"Small molecule","molecularWeight":"628.72"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"RTX targets CD20, a surface antigen expressed on B lymphocytes, leading to B cell depletion through antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). This reduces autoimmune-mediated inflammation and is used in conditions driven by pathogenic B cells and autoantibodies.","oneSentence":"RTX (rituximab) is a chimeric monoclonal antibody that depletes B cells by binding to CD20 antigen on their surface.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:32:57.051Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Systemic lupus erythematosus (SLE)"},{"name":"Lupus nephritis"}]},"trialDetails":[{"nctId":"NCT06186219","phase":"PHASE1","title":"Recapturing Immune Tolerance to Pegloticase for the Management of Tophaceous Gout","status":"COMPLETED","sponsor":"University of California, Los Angeles","startDate":"2024-04-10","conditions":"Tophaceous Gout","enrollment":2},{"nctId":"NCT04221035","phase":"PHASE3","title":"High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)","status":"RECRUITING","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2019-11-05","conditions":"High-Risk Neuroblastoma, Patient With Insufficient Response Chemoimmunotherapy","enrollment":800},{"nctId":"NCT06676631","phase":"PHASE1","title":"NK010 or NK042 in Combination With Rituximab for Refractory Systemic Lupus Erythematosus/Lupus Nephritis","status":"RECRUITING","sponsor":"Guangdong Provincial People's Hospital","startDate":"2025-02-19","conditions":"Refractory Systemic Lupus Erythematosus, Refractory Lupus Nephritis","enrollment":18},{"nctId":"NCT02378298","phase":"PHASE4","title":"Rituximab (RTX) Therapy in Patients With Active TAO","status":"COMPLETED","sponsor":"Göteborg University","startDate":"2011-12","conditions":"Ophthalmopathy, Thyroid-Associated","enrollment":38},{"nctId":"NCT03747159","phase":"PHASE3","title":"Synergetic B-cell Immunomodulation in SLE - 2nd Study.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Leiden University Medical Center","startDate":"2018-10-01","conditions":"Lupus Erythematosus, Systemic","enrollment":70},{"nctId":"NCT05679336","phase":"NA","title":"Rituximab, Cyclophosphamide, and Corticosteroids in Primary Membranous Nephropathy","status":"RECRUITING","sponsor":"St. Petersburg State Pavlov Medical University","startDate":"2018-05-01","conditions":"Membranous Nephropathy - PLA2R Induced","enrollment":40},{"nctId":"NCT06190457","phase":"","title":"Safety and Efficacy of Intrathecal Rituximab in 16 Children of Stage Ⅲ、ⅣNon-Hodgkin Lymphoma","status":"COMPLETED","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2015-09-30","conditions":"Lymphoma, Non-Hodgkin, Child, Only","enrollment":16},{"nctId":"NCT05824390","phase":"PHASE4","title":"A Randomized, Controlled Clinical Study of Rituximab in Treatment of Primary IgA Nephropathy","status":"UNKNOWN","sponsor":"XIEJINGYUAN","startDate":"2020-06-20","conditions":"IgA Nephropathy","enrollment":116},{"nctId":"NCT04585152","phase":"PHASE2","title":"Rituximab Versus Mycophenolate Mofetil in Children With Steroid-dependent Idiopathic Nephrotic Syndrome.","status":"UNKNOWN","sponsor":"Istituto Giannina Gaslini","startDate":"2020-10-15","conditions":"Nephrotic Syndrome Steroid-Dependent","enrollment":160},{"nctId":"NCT05116228","phase":"PHASE4","title":"Non-inferiority of Reduced-dose Rituximab in Rheumatoid Arthritis in Low Disease Activity and Remission","status":"TERMINATED","sponsor":"Medical University of Vienna","startDate":"2015-09-01","conditions":"Rheumatoid Arthritis, Remission","enrollment":21},{"nctId":"NCT02383589","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Rituximab Versus Mycophenolate Mofetil (MMF) in Participants With Pemphigus Vulgaris (PV)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2015-05-26","conditions":"Pemphigus Vulgaris","enrollment":135},{"nctId":"NCT04402580","phase":"PHASE2","title":"Efficacy of Anti-CD20 Antibodies (Rituximab Biosimilar) in the Treatment of Childhood Steroid-dependent Nephrotic Syndrome","status":"TERMINATED","sponsor":"Istituto Giannina Gaslini","startDate":"2019-07-01","conditions":"Nephrotic Syndrome Steroid-Dependent","enrollment":30},{"nctId":"NCT02394119","phase":"PHASE2","title":"Ofatumumab Versus Rituximab in Children With Steroid and Calcineurin Inhibitor Dependent Idiopathic Nephrotic Syndrome","status":"COMPLETED","sponsor":"Istituto Giannina Gaslini","startDate":"2015-06","conditions":"Nephrotic Syndrome","enrollment":140},{"nctId":"NCT02236936","phase":"PHASE3","title":"Parenteral Nutrition for Patients Treated for Locally Advanced Inoperable Tumors of the Head and Neck","status":"TERMINATED","sponsor":"Arbeitsgemeinschaft medikamentoese Tumortherapie","startDate":"2017-02-03","conditions":"Squamous Cell Carcinoma of the Hypopharynx Stage III, Squamous Cell Carcinoma of the Hypopharynx Stage IV, Laryngeal Squamous Cell Carcinoma Stage III","enrollment":8},{"nctId":"NCT01691898","phase":"PHASE1, PHASE2","title":"A Study of Pinatuzumab Vedotin (DCDT2980S) Combined With Rituximab or Polatuzumab Vedotin (DCDS4501A) Combined With Rituximab or Obinutuzumab in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2012-09-27","conditions":"Follicular Lymphoma, Diffuse Large B-Cell Lymphoma","enrollment":231},{"nctId":"NCT01576588","phase":"PHASE2","title":"Rituximab in Pretreated Elderly or Unfit B-CLL Patients","status":"COMPLETED","sponsor":"Prof. Dr. Med. Laimonas Griskevicius","startDate":"2011-10","conditions":"B-Cell Chronic Lymphocytic Leukemia","enrollment":25},{"nctId":"NCT01777750","phase":"NA","title":"Cooling in Myocardial Infarction","status":"COMPLETED","sponsor":"Medical University of Vienna","startDate":"2013-02","conditions":"ST-elevation Myocardial Infarction","enrollment":120},{"nctId":"NCT00813943","phase":"PHASE2","title":"Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Unmethylated Gene Promoter Status","status":"COMPLETED","sponsor":"EMD Serono","startDate":"2009-03","conditions":"Glioblastoma","enrollment":265},{"nctId":"NCT02966717","phase":"PHASE2","title":"Rituximab Combined With MSCs in the Treatment of PNS (3-4 Stage of CKD)","status":"UNKNOWN","sponsor":"Zhujiang Hospital","startDate":"2016-08","conditions":"Renal Insufficiency, Chronic, Nephrotic Syndrome","enrollment":116},{"nctId":"NCT02731560","phase":"PHASE4","title":"Rituximab (RTX) for Disease Modifying Anti Rheumatic Drug (DMARD) Non-responders in Pakistan: The Pakistan Rituximab Study (PARIS)","status":"COMPLETED","sponsor":"Prof. Abid Z. Farooqi","startDate":"2010-01","conditions":"Rheumatoid Arthritis","enrollment":74},{"nctId":"NCT01673295","phase":"PHASE3","title":"RING - Rituximab for Lupus Nephritis With Remission as a Goal","status":"UNKNOWN","sponsor":"Frédéric A. Houssiau, MD, PhD","startDate":"2014-11","conditions":"Lupus Nephritis","enrollment":194},{"nctId":"NCT01989858","phase":"PHASE3","title":"ITACA-S2 (Intergroup Trial in Adjuvant Chemotherapy for Adenocarcinoma of the Stomach)","status":"TERMINATED","sponsor":"Mario Negri Institute for Pharmacological Research","startDate":"2010-11","conditions":"Gastric Adenocarcinoma","enrollment":1180},{"nctId":"NCT00689221","phase":"PHASE3","title":"Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Methylated Gene Promoter Status","status":"COMPLETED","sponsor":"EMD Serono","startDate":"2008-09","conditions":"Glioblastoma","enrollment":545},{"nctId":"NCT01864343","phase":"NA","title":"Target Temperature Management In Myocardial Infarction - A Pilot Study","status":"COMPLETED","sponsor":"Medical University of Vienna","startDate":"2011-09","conditions":"ST-elevation Myocardial Infarction","enrollment":19}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":53,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"RTX infusions","genericName":"RTX infusions","companyName":"Frédéric A. Houssiau, MD, PhD","companyId":"fr-d-ric-a-houssiau-md-phd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"RTX (rituximab) is a chimeric monoclonal antibody that depletes B cells by binding to CD20 antigen on their surface. Used for Systemic lupus erythematosus (SLE), Lupus nephritis.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}